Dynamic Alterations of the Gut Microbial Pyrimidine and Purine Metabolism in the Development of Liver Cirrhosis

• Published in: Frontiers in molecular biosciences Vol. 8; p. 811399
• Main Authors: Xiong, Yinghui, Wu, Li, Shao, Li, Wang, Yang, Huang, Zebing, Huang, Xun, Li, Chunhui, Wu, Anhua, Liu, Zhenguo, Fan, Xuegong, Zhou, Pengcheng
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 28-01-2022
• Subjects: fecal metabolomics; gut microbiota; liver cirrhosis; metagenomics sequencing; Molecular Biosciences; pyrimidine and purine metabolism; metagenomics sequencing; fecal metabolomics; pyrimidine and purine metabolism; gut microbiota; liver cirrhosis
• ISSN: 2296-889X; 2296-889X
• DOI: 10.3389/fmolb.2021.811399

Liver cirrhosis is the common end-stage of liver disease which lacks effective treatment, thus studies to determine prevention targets are an urgent need. The intestinal microbiota (IM) play important roles in modulating liver diseases which are mediated by microbial metabolites. Despite decades of growing microbial studies, whether IM contribute to the development of cirrhosis and the intimate metabolic link remain obscure. Here, we aimed to reveal the dynamic alterations of microbial composition and metabolic signatures in carbon tetrachloride (CCl
)-induced liver cirrhosis mice.
CCl
-treated mice or normal control (NC) were sacrificed (
= 10 per group) after 5 and 15 weeks of intervention. The disease severity was confirmed by Masson's trichrome or Sirius red staining. Metagenomics sequencing and fecal untargeted metabolomics were performed to evaluate the composition and metabolic function of IM in parallel with the development of cirrhosis.
The CCl
-treated mice presented liver fibrosis at 5 weeks and liver cirrhosis at 15 weeks indicated by collagen deposition and pseudo-lobule formation, respectively. Mice with liver cirrhosis showed distinct microbial composition from NC, even in the earlier fibrosis stage. Importantly, both of the liver fibrosis and cirrhosis mice were characterized with the depletion of Deltaproteobacteria (
< 0.05) and enrichment of Akkermansia (
< 0.05). Furthermore, fecal metabolomics revealed distinguished metabolomics profiles of mice with liver fibrosis and cirrhosis from the NC. Notably, pathway enrichment analysis pointed to remarkable disturbance of purine (
< 0.001 at 5 weeks,
= 0.034 at 15 weeks) and pyrimidine metabolic pathways (
= 0.005 at 5 weeks,
= 0.006 at 15 weeks) during the development of liver cirrhosis. Interestingly, the disorders of pyrimidine and purine metabolites like the known microbial metabolites thymidine and 2'-deoxyuridine had already occurred in liver fibrosis and continued in cirrhosis.
These novel findings indicated the crucial role of IM-modulated pyrimidine and purine metabolites in the development of liver cirrhosis, which provides microbial targets for disease prevention.